Cullinan Therapeutics Files DEF 14A on Executive Compensation
Ticker: CGEM · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1789972
| Field | Detail |
|---|---|
| Company | Cullinan Therapeutics, Inc. (CGEM) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, corporate-governance, proxy-statement
Related Tickers: CGEM
TL;DR
Cullinan Therapeutics (CGEM) filed its DEF 14A, showing exec comp details for FY24. Look out for equity award vesting and fair value changes.
AI Summary
Cullinan Therapeutics, Inc. filed a DEF 14A on April 25, 2025, detailing executive compensation and corporate governance matters for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted and vested for individuals like Mary Kay Fenton, and changes in the fair value of these awards. The company, formerly known as Cullinan Oncology, Inc., is in the biological products sector.
Why It Matters
This filing provides transparency into how Cullinan Therapeutics compensates its top executives and board members, which can influence investor decisions and perceptions of corporate governance.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing related to executive compensation and corporate governance, not indicating immediate operational or financial distress.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for compensation details)
- 20250425 — Filing Date (Date the DEF 14A was submitted to the SEC)
Key Players & Entities
- Cullinan Therapeutics, Inc. (company) — Filer of the DEF 14A
- Mary Kay Fenton (person) — Executive mentioned in relation to equity awards
- Cullinan Oncology, Inc. (company) — Former name of the company
- Cullinan Management, Inc. (company) — Former name of the company
- Cullinan Oncology, LLC (company) — Former name of the company
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is used to solicit shareholder votes and provides detailed information about matters to be voted on at a shareholder meeting, including executive compensation, director elections, and other corporate governance issues.
When was Cullinan Therapeutics, Inc. formerly known as Cullinan Oncology, Inc.?
Cullinan Therapeutics, Inc. changed its name from Cullinan Oncology, Inc. on February 25, 2021.
What type of business is Cullinan Therapeutics, Inc. primarily involved in?
Cullinan Therapeutics, Inc. is primarily involved in Biological Products (No Diagnostic Substances), with SIC code 2836.
Who is mentioned in the filing in relation to equity awards for the 2024 fiscal year?
Mary Kay Fenton is mentioned in the filing in relation to equity awards granted and vested during the 2024 fiscal year.
What is the business address of Cullinan Therapeutics, Inc.?
The business address of Cullinan Therapeutics, Inc. is One Main Street, Suite 1350, Cambridge, MA 02142.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 by Mary Kay Fenton regarding Cullinan Therapeutics, Inc. (CGEM).